See more : Beeks Trading Corporation Ltd. (BKS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Precision BioSciences, Inc. (DTIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precision BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Orient Electric Limited (ORIENTELEC.NS) Income Statement Analysis – Financial Results
- Compagnie Financière Richemont SA (CFRUY) Income Statement Analysis – Financial Results
- Zhejiang Huakang Pharmaceutical Co., Ltd. (605077.SS) Income Statement Analysis – Financial Results
- Ribomic Inc. (4591.T) Income Statement Analysis – Financial Results
- Conifer Holdings, Inc. (CNFRZ) Income Statement Analysis – Financial Results
Precision BioSciences, Inc. (DTIL)
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 48.73M | 25.10M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Cost of Revenue | 8.26M | 9.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 40.47M | 16.09M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Gross Profit Ratio | 83.06% | 64.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 53.38M | 83.94M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.10M |
General & Administrative | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 6.10M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.76M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.20M |
Cost & Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.84M |
Interest Income | 7.69M | 3.47M | 208.00K | 822.00K | 4.27M | 1.88M | 872.00K | 570.00K |
Interest Expense | 2.23M | 1.11M | 132.00K | 0.00 | 182.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 8.26M | 9.00M | 10.20M | 9.81M | 5.32M | 2.35M | 1.44M | 640.00K |
EBITDA | -32.04M | -62.79M | -20.27M | -99.19M | -87.38M | -43.68M | -20.42M | -8.19M |
EBITDA Ratio | -65.76% | -392.35% | -24.94% | -408.45% | -392.92% | -418.62% | -313.12% | -116.72% |
Operating Income | -43.74M | -100.37M | -39.40M | -109.83M | -87.20M | -47.91M | -21.97M | -8.83M |
Operating Income Ratio | -89.76% | -399.90% | -34.11% | -452.25% | -392.14% | -440.25% | -338.90% | -125.84% |
Total Other Income/Expenses | 1.21M | 27.46M | 8.80M | 822.00K | -5.67M | 1.88M | 872.00K | 572.00K |
Income Before Tax | -42.53M | -111.64M | -30.60M | -109.01M | -92.88M | -46.04M | -21.10M | -8.26M |
Income Before Tax Ratio | -87.28% | -444.80% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
Income Tax Expense | 0.00 | 11.27M | 316.00K | 10.43M | -9.58M | 1.88M | -754.00K | -5.00K |
Net Income | -61.32M | -122.91M | -30.92M | -109.01M | -83.30M | -46.04M | -21.10M | -8.25M |
Net Income Ratio | -125.84% | -489.71% | -26.76% | -448.86% | -374.59% | -423.02% | -325.45% | -117.62% |
EPS | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
EPS Diluted | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
Weighted Avg Shares Out | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Weighted Avg Shares Out (Dil) | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Precision BioSciences to Participate in Upcoming June Investor Conferences
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
Source: https://incomestatements.info
Category: Stock Reports